KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Outstanding
Ratios

CRISPR Therapeutics AG (CRSP) Leases (2019 - 2025)

Historic Leases for CRISPR Therapeutics AG (CRSP) over the last 7 years, with Q4 2025 value amounting to $131.7 million.

  • CRISPR Therapeutics AG's Leases fell 818.13% to $131.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $131.7 million, marking a year-over-year decrease of 818.13%. This contributed to the annual value of $131.7 million for FY2025, which is 818.13% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Leases stood at $131.7 million for Q4 2025, which was down 818.13% from $134.7 million recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Leases peaked at $179.4 million during Q2 2021, and registered a low of $50.1 million during Q1 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Leases had a median value of $153.7 million in 2023 and averaged $149.6 million.
  • In the last 5 years, CRISPR Therapeutics AG's Leases surged by 35647.5% in 2021 and then tumbled by 1060.68% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Leases (Quarter) stood at $174.5 million in 2021, then decreased by 10.05% to $156.9 million in 2022, then dropped by 1.87% to $154.0 million in 2023, then dropped by 6.84% to $143.5 million in 2024, then fell by 8.18% to $131.7 million in 2025.
  • Its Leases stands at $131.7 million for Q4 2025, versus $134.7 million for Q3 2025 and $137.6 million for Q2 2025.